{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:58:39Z","timestamp":1780055919740,"version":"3.54.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ZonMw"},{"name":"Auris | J&J | Janssen Pharmaceuticals"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,9]]},"abstract":"<jats:p>T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. B-cell maturation antigen (BCMA) exhibits high expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition of \u03b3-secretase. BCMA is considered a validated target in multiple myeloma but whether mature B-cell lymphomas can be targeted by the BCMAxCD3 T-cell redirector teclistamab is currently unknown. BCMA expression on B-cell non\u2013Hodgkin lymphoma and primary chronic lymphocytic leukemia (CLL) cells was assessed by flow cytometry and\/or IHC. To assess teclistamab efficacy, cells were treated with teclistamab in presence of effector cells with\/without \u03b3-secretase inhibition. BCMA could be detected on all tested mature B-cell malignancy cell lines, while expression levels varied per tumor type. \u03b3-secretase inhibition universally increased BCMA surface expression. These data were corroborated in primary samples from patients with Waldenstrom's macroglobulinemia, CLL, and diffuse large B-cell lymphoma. Functional studies with the B-cell lymphoma cell lines revealed teclistamab-mediated T-cell activation, proliferation, and cytotoxicity. This was independent of the level of BCMA expression, but generally lower in mature B-cell malignancies compared with multiple myeloma. Despite low BCMA levels, healthy donor T cells and CLL-derived T cells induced lysis of (autologous) CLL cells upon addition of teclistamab. These data show that BCMA is expressed on various B-cell malignancies and that lymphoma cell lines and primary CLL can be targeted using teclistamab. Further studies to understand the determinants of response to teclistamab are required to identify which other diseases might be suitable for teclistamab targeting.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Besides reported BCMA expression on multiple myeloma, we demonstrate BCMA can be detected and enhanced using \u03b3-secretase inhibition on cell lines and primary material of various B-cell malignancies. Furthermore, using CLL we demonstrate that low BCMA-expressing tumors can be targeted efficiently using the BCMAxCD3 DuoBody teclistamab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0083","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:18:57Z","timestamp":1651051137000},"page":"330-341","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Redirecting T-cell Activity with Anti-BCMA\/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas"],"prefix":"10.1158","volume":"2","author":[{"given":"Anne W.J.","family":"Martens","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"3Cancer Center Amsterdam, Amsterdam, the Netherlands."},{"name":"4Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Rietveld","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"de Boer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur S.","family":"Peters","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"3Cancer Center Amsterdam, Amsterdam, the Netherlands."},{"name":"4Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Ngo","sequence":"additional","affiliation":[{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte W.H.G.","family":"van Mil","sequence":"additional","affiliation":[{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"de Heer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"5Department of Hematology, Flevoziekenhuis, Almere, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Spaargaren","sequence":"additional","affiliation":[{"name":"3Cancer Center Amsterdam, Amsterdam, the Netherlands."},{"name":"6Department of Pathology, University of Amsterdam, the Netherlands."},{"name":"7Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-207X","authenticated-orcid":true,"given":"Christie P.M.","family":"Verkleij","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-4591","authenticated-orcid":true,"suffix":"III","given":"Homer C.","family":"Adams","sequence":"additional","affiliation":[{"name":"9Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-6640","authenticated-orcid":true,"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[{"name":"2Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"3Cancer Center Amsterdam, Amsterdam, the Netherlands."},{"name":"4Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands."},{"name":"7Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-7390","authenticated-orcid":true,"given":"Carel J.M.","family":"van Noesel","sequence":"additional","affiliation":[{"name":"6Department of Pathology, University of Amsterdam, the Netherlands."},{"name":"7Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":true,"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[{"name":"9Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":true,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands."},{"name":"3Cancer Center Amsterdam, Amsterdam, the Netherlands."},{"name":"4Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands."},{"name":"7Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers12123837","article-title":"Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma","volume":"12","author":"Van Bruggen","year":"2020","journal-title":"Cancers"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"e000218","DOI":"10.1136\/jitc-2019-000218","article-title":"CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells","volume":"8","author":"Martens","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"2023030220213889000_","first-page":"5","article-title":"Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia","author":"Portell","year":"2013","journal-title":"Clin Pharmacol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'connor","year":"2004","journal-title":"J Exp Med"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.4049\/jimmunol.179.11.7276","article-title":"Regulated expression of BAFF-binding receptors during human B cell differentiation","volume":"179","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.12645","article-title":"B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL","volume":"164","author":"Ferrer","year":"2014","journal-title":"Br J Haematol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"Van Der Veer","year":"2011","journal-title":"Haematologica"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"Van Der Veer","year":"2011","journal-title":"Blood Cancer J"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy","volume":"134","author":"Van Bruggen","year":"2019","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1755-5949.2010.00164.x","article-title":"REVIEW: gamma-Secretase inhibitors for the treatment of Alzheimer's disease: The current state","volume":"16","author":"Panza","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Tolcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","article-title":"Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors","volume":"30","author":"Krop","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","article-title":"A phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014","volume":"21","author":"Messersmith","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/leu.2017.90","article-title":"NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components","volume":"31","author":"Pozzo","year":"2017","journal-title":"Leukemia"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","article-title":"TIGIT and PD-1 mark intratumoral T Cells with reduced effector function in B-cell non-hodgkin lymphoma","volume":"7","author":"Josefsson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3109\/10428194.2012.673224","article-title":"Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia","volume":"53","author":"Tonino","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2023030220213889000_","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2011-03-340646","article-title":"Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation","volume":"118","author":"Hilchey","year":"2011","journal-title":"Blood"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0083\/3119216\/crc-22-0083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/5\/330\/3279536\/crc-22-0083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/5\/330\/3279536\/crc-22-0083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:44:35Z","timestamp":1700487875000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/5\/330\/696317\/Redirecting-T-cell-Activity-with-Anti-BCMA-Anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,9]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0083","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550694.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544582","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544582.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550694","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]}}}